Professor Maher Gandhi


Executive Director of Mater Research; Director Mater Research Institute-UQ; Haematologist (Princess Alexandra and Mater Hospitals)

Research Themes

Cancer and Blood Diseases


Biomarkers for lymphoma

Currently involved in Biomarkers for Lymphoma, a TRI based research project.

Cell-based immunotherapy for relapsed diffuse B-cell lymphoma

In a project funded by the MRFF Rare Cancers, Rare Disease and Unmet Needs Clinical Trials Program, Prof Gandhi is leading a multi-site Phase I clinical trial to investigate the application of cell-based immunotherapies for relapsed diffuse B-cell lymphoma. For more information, see here.


About me

Professor Maher Gandhi is CEO of Mater Research and Director of Mater Research Institute-UQ, and a pre-eminent senior staff haematologist.

Professor Maher’s role is to set strategy and create a clinical research program that influences future national and international health policy and practice through the full integration of Mater Research with clinical care. Whilst centred on Mater Research, the role also has close involvement with Mater Health, Mater Education and Mater Foundation.

Professor Gandhi joins Mater from the Diamantina Institute, The University of Queensland and as a Pre-Eminent Senior Staff Haematologist and Head of Academic Haematology at the Princess Alexandra Hospital. A Specialist Haematologist for 16 years, Maher’s medical speciality training was completed in the UK in Cambridge and Newcastle-Upon-Tyne, and in Toronto Canada. He completed a PhD in Viral Immunology in Cambridge, came to Brisbane on a Fellowship in 2003, and has stayed in Brisbane supported by uninterrupted NHMRC funding since 2005.

His past appointments include Chair of the Australasian Leukaemia Lymphoma Group Scientific Sub-Committee and Chair of the Metro South HREC. Professor Gandhi’s research interests relate to the tumour microenvironment in lymphoma. He is passionate about promoting translational research and personalised medicine, implementing interdisciplinary research, innovative clinical trials, and forging stronger links between scientists and clinicians.